In the setting of advanced prostatic cancer disease and castration-resistant metastatic PC, PSMA PET/CT plays an important role in targeting 177Lutetium-PSMA radioligand therapy and treatment response assessment [31]. The gene discussed is FOLH1; the disease is pachyonychia congenita.